Education
About Us
Working with TipRanks
Follow Us
ADMA Biologics (ADMA)
NASDAQ:ADMA
Total Valuation
ADMA Biologics has a market cap or net worth of $4.88B. The enterprise value is ―.
Market Cap$4.88B
Enterprise Value―
Share Statistics
ADMA Biologics has 238,734,250 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding238,734,250
Owned by Insiders3.26%
Owned by Institutions14.75%
Financial Efficiency
ADMA Biologics’s return on equity (ROE) is 0.57 and return on invested capital (ROIC) is 50.31%.
Return on Equity (ROE)0.57
Return on Assets (ROA)0.40
Return on Invested Capital (ROIC)50.31%
Return on Capital Employed (ROCE)0.32
Revenue Per Employee622.56K
Profits Per Employee0.00
Employee Count685
Asset Turnover0.87
Inventory Turnover1.22
Valuation Ratios
The current PE Ratio of ADMA Biologics is 20.22. ADMA Biologics’s PEG ratio is 0.13.
PE Ratio20.22
PS Ratio0.00
PB Ratio13.44
Price to Fair Value11.45
Price to FCF42.68
Price to Operating Cash Flow39.53
PEG Ratio0.13
Income Statement
In the last 12 months, ADMA Biologics had revenue of 426.45M and earned 197.67M in profits. Earnings per share was 0.85.
Revenue426.45M
Gross Profit219.55M
Operating Income138.98M
Pretax Income125.71M
Net Income197.67M
EBITDA147.69M
Earnings Per Share (EPS)0.85
Cash Flow
In the last 12 months, operating cash flow was 118.67M and capital expenditures -8.22M, giving a free cash flow of 110.45M billion.
Operating Cash Flow118.67M
Free Cash Flow110.45M
Free Cash Flow per Share0.46
Dividends & Yields
ADMA Biologics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.04
52-Week Price Change90.45%
50-Day Moving Average20.69
200-Day Moving Average18.70
Relative Strength Index (RSI)45.77
Average Volume (3m)3.41M
Important Dates
ADMA Biologics upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
ADMA Biologics as a current ratio of 5.97, with Debt / Equity ratio of 23.53%
Current Ratio5.97
Quick Ratio2.90
Debt to Market Cap0.02
Net Debt to EBITDA-0.14
Interest Coverage Ratio9.98
Taxes
In the past 12 months, ADMA Biologics has paid -71.96M in taxes.
Income Tax-71.96M
Effective Tax Rate-0.57
Enterprise Valuation
ADMA Biologics EV to EBITDA ratio is 26.92, with an EV/FCF ratio of 33.51.
EV to Sales9.32
EV to EBITDA26.92
EV to Free Cash Flow33.51
EV to Operating Cash Flow33.51
Balance Sheet
ADMA Biologics has $103.15M in cash and marketable securities with $82.12M in debt, giving a net cash position of -$21.03M billion.
Cash & Marketable Securities$103.15M
Total Debt$82.12M
Net Cash-$21.03M
Net Cash Per Share-$0.09
Tangible Book Value Per Share$1.48
Margins
Gross margin is 51.40%, with operating margin of 32.59%, and net profit margin of 46.35%.
Gross Margin51.40%
Operating Margin32.59%
Pretax Margin29.48%
Net Profit Margin46.35%
EBITDA Margin34.63%
EBIT Margin32.75%
Analyst Forecast
The average price target for ADMA Biologics is $30.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$30.67
Price Target Upside53.81% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast62.22%
EPS Growth Forecast―